Who is eligible for clinical trial NCT01357668?

Participants must meet protocol criteria for Juvenile Idiopathic Arthritis. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT01357668 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-09-24

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis (NCT01357668)

🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Bristol-Myers Squibb

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.

Who can join: Review the eligibility criteria below.

Location: Local Institution - 0060 — Little Rock, Arkansas

Age range: Not specified to 17 Years

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (59 Sites)

Showing the first 25 of 59 sites.

Local Institution - 0060 — Little Rock, Arkansas
Local Institution - 0001 — Princeton, New Jersey
Local Institution - 0059 — Cincinnati, Ohio
Local Institution - 0025 — Bregenz,
Local Institution - 0002 — Innsbruck,
Local Institution - 0032 — Vienna,
Local Institution - 0010 — Botucatu, São Paulo
Local Institution - 0026 — Campinas, São Paulo
Local Institution - 0028 — São Paulo, São Paulo
Local Institution - 0027 — Rio de Janeiro,
Local Institution - 0029 — Calgary, Alberta
Local Institution - 0011 — Montreal, Quebec
Local Institution - 0035 — Aarhus, Central Jutland
Local Institution - 0012 — Copenhagen,
Local Institution - 0040 — Clermont-Ferrand, Puy-de-Dôme
Local Institution - 0005 — Paris,
Local Institution - 0041 — Toulouse,
Local Institution - 0003 — Bad Bramstedt,
Local Institution - 0030 — Berlin,
Local Institution - 0034 — Freiburg im Breisgau,
Local Institution - 0031 — Hamburg,
Local Institution - 0033 — Heidelberg,
Local Institution - 0016 — Thessaloniki,
Local Institution - 0017 — Budapest,
Local Institution - 0014 — Jerusalem,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Juvenile Idiopathic Arthritis

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. — Phoenix, Arizona
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) — San Miguel de Tucumán, Tucumán Province
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis — Rosario,
M3-JIA: Making Mindfulness Matter for Children With JIA — Hamilton, Ontario
UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease — Calgary, Alberta

Explore by condition: All Juvenile Idiopathic Arthritis clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗